Headquartered in Northbrook, Illinois, with offices in New Jersey and Chicago, Marathon Pharmaceuticals researches on developing treatments of rare diseases such as uncommon cancers and neurological disorders. It concentrates on small volume but complex treatments unlike big companies doing research in the field of biopharmaceutical field.
The research on cures and treatments of such diseases aligns with the mission of Marathon Pharma. They are involved in developing medications difficult to manufacture, for example, Amytal Sodium, a barbiturate derivative used as a sedative-hypnotic used for insomnia and anesthetic for surgeries. Barbiturates can be defined as central nervous system depressants, which decrease motor activity and induce drowsiness and even hypnosis.
Marathon also developed a histamine H2-receptor called PEPCID, used to relieve heartburn by reducing the secretion of acid in the stomach. It is prescribed for the treatment of duodenal ulcers as well as gastroesophageal reflux disease. They also marketed opium tincture, a hydroalcoholic solution for the treatment of diarrhea by reducing enzyme secretions and contractions of muscles.
The most popular product of Marathon Pharma is lidocaine hydrochloride monohydrate also called ZiNGO. It is designed for people of ages 3 to 18 years who face anxiety to injections. It is a needleless simple device used as an anesthetic and causes no pain. The use and throw device is used to deliver 0.5mg of lidocaine in its powder form through the skin by the help of a helium-powered mechanism, with the push of a button. It takes a maximum of 3 minutes of numb the targeted site. The effect lasts for 10 minutes. This device requires no refrigeration.
According to William T. Zempsky, MD, Professor of Pediatrics and Division Head of Pain and Palliative Medicine at Connecticut Children’s Medical Center, ZinGO is a revolutionary device that is quick to act without the fear of needles and the effect lasting too long.
Mainstream anesthetic products take almost an hour to work and prove to be disadvantageous in a fast-paced healthcare environment, sacrificing the comfort of patients during multiple venous access procedure every day. It is a huge relief to children and parents. After successful trials of ZiNGO, they marketed it by partnering with Medline, a global distributor of medical. This step brought top-notch healthcare professionals together to focus on patient care and the efficient execution of intravenous procedures.